PLG and cancer: While TA has been used to manage cancer and cancer treatment-associated sequela in patients (Soma et al., 1980; Kikuchi et al., 1986; Oertli et al., 1994; Wu et al., 2006; Longo et al., 2018; Lohani et al., 2020; Jaffer et al., 2021; Lohani et al., 2021), it has never been used clinically as an anti-cancer therapeutic, and considerations of TA anticancer actions have focused on its blockade of Plasmin production.